Tissue Regenix’s interim results are in line with our expectations and demonstrate the progress the company is making to achieve various milestones in each of its divisions. In particular, its Wound Care division made important progress in its commercialisation and achieved 510k market clearance for its SurgiPure XD product and increased its Medicare coverage for DermaPure (to 93%). We have increased our valuation to £364m (previously £338m) due to an updated exchange rate (
19 Oct 2016
Interim results underpin expectations
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Interim results underpin expectations
Tissue Regenix Group plc (TRX:LON) | 62.5 0 0.0% | Mkt Cap: 44.1m
- Published:
19 Oct 2016 -
Author:
Dr Linda Pomeroy -
Pages:
3
Tissue Regenix’s interim results are in line with our expectations and demonstrate the progress the company is making to achieve various milestones in each of its divisions. In particular, its Wound Care division made important progress in its commercialisation and achieved 510k market clearance for its SurgiPure XD product and increased its Medicare coverage for DermaPure (to 93%). We have increased our valuation to £364m (previously £338m) due to an updated exchange rate (